Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000059.xml
Pneumologie 2021; 75(04): 259-260
DOI: 10.1055/a-1373-9381
DOI: 10.1055/a-1373-9381
Stellungnahme
COVID-19-Impfungen bei Biologika-Therapie von Asthma bronchiale
Stellungnahme der Deutschen Gesellschaft für Pneumologie (DGP) und der Österreichischen Gesellschaft für Pneumologie (ÖGP)COVID-19 Vaccination in Asthma Patients Treated with BiologicalsStatement of the Austrian Society of Pneumology and German Respiratory Society
Zusammenfassung
Für Patienten und Patientinnen mit Asthma wird eine Impfung gegen COVID-19 empfohlen. Dies gilt auch für Patienten und Patientinnen mit schwerem Asthma. Die Behandlung des schweren Asthmas mit einem Biologikum ist keine Kontraindikation für eine Impfung gegen COVID-19.
Abstract
Patients with asthma should be vaccinated against COVID-19. This includes patients with severe asthma. Treatment with a biological for asthma is no contra-indication for vaccination against COVID-19.
Publication History
Article published online:
12 March 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Ewer KJ, Barrett JR, Belij-Rammerstorfer S. et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 2020; DOI: 10.1038/s41591-020-01194-5.
- 2 Zeitlin PL, Leong M, Cole J. et al. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial. J Asthma Allergy 2018; 11: 181-192 DOI: 10.2147/JAA.S172338.
- 3 Blauvelt A, Simpson EL, Tyring SK. et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol 2019; 80: 158-167 DOI: 10.1016/j.jaad.2018.07.048.
- 4 Dicks MDJ, Spencer AJ, Edwards NJ. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 2012; 7: e40385 DOI: 10.1371/journal.pone.0040385.
- 5 Krammer F. SARS-CoV-2 vaccines in development. Nature 2020; 586: 516-527 DOI: 10.1038/s41586-020-2798-3.